Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Aarden, absorption, Aravive, awaiting, azacitidine, Beleodaq, BioAtla, Blueprint, Botany, Boxer, bribery, Bruce, capmatinib, Carter, Celldex, Christopher, confirmatory, Conforma, Corning, Corrupt, deletion, depleting, dried, DSP, Elizabeth, Enanta, England, exceptionally, excretion, Exon, Farydak, FCPA, gel, hodgkin, Hoosier, immunogenic, immunogenicity, KDR, KIT, Les, licensure, London, longest, Loxo, Lybrand, macrophage, Manchester, Mer, metastatic, Microbiology, microenvironment, multi, multicenter, myeloma, Nordisk, Novo, Ono, passage, PDGFRA, Promosome, prototype, Qiagen, QLT, Queen, Reddy, repeal, resolution, SCLC, SDD, Seattle, Servier, soft, Sorrento, spray, step, supplier, Symphogen, thought, tolerogenic, Tragara, Tyro, unconfirmed, unknown, unreported, Xencor
Removed:
accountancy, added, amounting, applying, apportioned, bank, BCC, BID, biologic, buying, CA, CardioNet, category, closed, closure, collection, committed, connected, conversion, converted, Creation, DDR, deducted, delisting, diffuse, dollar, enterprise, financed, follicular, fourth, gergen, initiating, Jaffray, Job, Leerink, median, Medtronic, Middle, Minnesota, Minot, Montreal, MYG, neck, nondeductible, occupancy, offsetting, operated, outpatient, overhead, percent, Piper, proportionate, published, pursued, Quebec, represented, revalued, reversed, Swann, therefrom, translated, translation, trk, underwriting, Vidaza, violate, vivo
Filing tables
Filing exhibits
Related press release
MRTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-207848) of Mirati Therapeutics, Inc., |
(2) | Registration Statement (Form S-3 No. 333-206965) of Mirati Therapeutics, Inc., |
(3) | Registration Statement (Form S-3 No. 333-198678) of Mirati Therapeutics, Inc., |
(4) | Registration Statement (Form S-8 No. 333-204720) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc., |
(5) | Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc., and |
(6) | Registration Statement (Form S-8 No. 333-196487) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics Inc.; |
of our report dated March 9, 2017, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP | ||||
San Diego, California | ||||
March 9, 2017 | ||||